Results 81 to 90 of about 9,311 (148)

Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder. [PDF]

Case Rep Neurol Med
Tsuzaki K, Mitsui G, Inagaki Y, Uehara N, Wada S, Hamano T.   +5 more
europepmc   +1 more source

Successful living kidney transplantation in a T-cell flow cytometry crossmatch-positive patient with atypical hemolytic uremic syndrome treated with an anti-C5 antibody: a case report. [PDF]

CEN Case Rep
Okumi M, Okuno N, Kurose R, Segawa Y, Komaki K, Miyashita M, Ueda T, Ukimura O, Tamagaki K.   +8 more
europepmc   +1 more source

Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria. [PDF]

EJHaem
Latyshev V, Fidarova Z, Lukina E, Parovichnikova E.   +3 more
europepmc   +1 more source

Paroxysmal Nocturnal Haemoglobinuria-Associated Acute Cutaneous Thrombosis and Haemolysis in the Setting of Parvovirus B19 and Varicella Zoster Virus Infection. [PDF]

EJHaem
Potter LJ, Trikha R, Gandhi S, Large J, Basu TN, Boissiere J, Devine H, Sugai T, Rasool A, Kulasekararaj A.   +9 more
europepmc   +1 more source

Complement C5 inhibition with eculizumab or ravulizumab is associated with increased cardiovascular and thromboembolic risk after ST-elevation myocardial infarction: a propensity-matched global retrospective cohort study. [PDF]

BMC Cardiovasc Disord
Vahldieck C.
europepmc   +1 more source

Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta-Analysis of Randomized Trials. [PDF]

EJHaem
Ishaque R, Talpur AS, Sidra H, Memon H, Memon FT, Talat F, Rafiq T, Rayamajhi S.   +7 more
europepmc   +1 more source

Effectiveness and Safety of Eculizumab in Highly Active AChR+gMG and Its Therapeutic Response in Different Subtypes of gMG. [PDF]

Immunotargets Ther
Ma T, Liu Y, Zhu Y, Gao Y, Wang X, Liang Y, Wang B, Zhu R.   +7 more
europepmc   +1 more source

Use of narsoplimab for eculizumab-refractory adult transplant-associated thrombotic microangiopathy (TA-TMA). [PDF]

Ann Hematol
Young S, Varadarajan I.
europepmc   +1 more source

Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study. [PDF]

Ann Hematol
Iori AP, De Vivo A, Di Bona E, Caocci G, Fioritoni F, Ciceri F, Beggiato E, Rapezzi D, Amendola A, Figuera A, Selleri C, Longu F, Fattizzo B, Tucci A, Cignetti A, Amico V, Sica S, Metafuni E, Raso S, Urbano TA, Marano L, Di Renzo N, Spedini P, Rambaldi A, Lanza F, Clissa C, Danesin C, Greve MB, Cabibbo S, Ori A, Cassanelli F, Sottana F, Campolo B, Gasparri G, Carini F, Barcellini W.   +35 more
europepmc   +1 more source

Efficacy and safety of vemircopan as monotherapy in patients with paroxysmal nocturnal hemoglobinuria. [PDF]

Blood Adv
Kulasekararaj A, Browett P, Risitano AM, Patriquin CJ, Yenerel MN, Marceau D, Sahin F, Algarra JL, Ogawa M, Yu J, Cross NB, Notaro R, Lee JW, Brodsky RA.   +13 more
europepmc   +1 more source